Develops immuno-oncology combination therapies, partnered with Gilead, for lung and gastrointestinal cancers.
Develops immuno-oncology combination therapies, partnered with Gilead, for lung and gastrointestinal cancers.
Revenue comes from Gilead, which since a 2020 deal has paid up front, shares development costs and owes milestone payments as drugs advance, while no Arcus drug is yet sold. Gilead is also a major shareholder, tying the two companies' fortunes together.
Moat: narrow (IP / patents). Broad immuno-oncology combination pipeline backed by a major Gilead partnership, but unproven vs standard of care.
Headquarters: Hayward, California, US · Founded: 2015 · Employees: 601
Size Arcus Biosciences (RCUS) is a United States Health Care company (Biotechnology) with a market value of $2.27B, the 1698th largest of 3,085 United States companies the cockpit tracks. Shares closed at $15.76 on 18 Nov 2026.
Performance Over six months the shares fell 33.6%, against -4.8% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue fell 58.3% over the last twelve months (peer median +9.4%); the operating margin is -475.0% (peer median -15.4%).
Valuation It trades at 17.6× enterprise value to sales against a peer median of 9.4× (5th most expensive of 15).
Backlog Backlog (remaining performance obligations) was $256M at 31 Dec 2025, down 51% on a year earlier — 1.0 years of trailing revenue. Backlog detail →
Short interest Short interest is 9.2% of the free float (30 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $100M | $247M | $258M | $117M | $112M |
| Revenue growth | — | -4% | +121% | +4% | — |
| Gross profit | $91.0M | $237M | $248M | $101M | $98.0M |
| EBITDA | -$466M | -$376M | -$300M | -$324M | -$266M |
| Net income | -$453M | -$353M | -$283M | -$307M | -$267M |
| Free cash flow | -$466M | -$484M | -$176M | -$330M | $432M |
| Capital expenditure | $1.00M | $2.00M | $6.00M | $24.0M | $6.00M |
| Total debt | $116M | $198M | $159M | $121M | $120M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Arcus Biosciences RCUS | $2.27B | -34% | -58% | -475% | 17.6× | n/a |
| Gilead Sciences GILD | $210B | +30% | +7% | 38% | 7.3× | -2.4% |
| Merck & MRK | $340B | +23% | +5% | 18% | 5.7× | 8.3% |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RCUS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -33.6% | -1.8% | lowest of 21 |
| 6-month return | -33.6% | -4.8% | 2nd lowest of 20 |
| Distance from 52-week high | -50.3% | -32.8% | 5th lowest of 21 |
| Revenue growth (TTM) | -58.3% | +9.4% | 4th lowest of 17 |
| Operating margin | -475.0% | -15.4% | 2nd lowest of 15 |
| EV / Sales | 17.6× | 9.4× | 5th most expensive of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Arcus Biosciences RCUS | United States | $2.27B | -34% | -58% | -475% | 17.6× | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.26B | +31% | +223% | 64% | n/a | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +51% | +8% | 19% | 5.0× | 13.4% | +44.5% |
| SKBS 302440.KS | South Korea | $2.25B | -12% | +11% | -23% | 4.3× | n/a | n/a |
| Pharvaris PHVS | United States | $2.21B | +7% | n/a | n/a | n/a | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.33B | -59% | 0% | -25% | 19.4× | n/a | n/a |
| Beam Therapeutics BEAM | United States | $2.17B | -22% | +163% | -268% | 9.4× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.16B | -11% | -94% | -211,685% | 9,677.0× | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.16B | -30% | -50% | 46% | 0.4× | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.14B | +27% | -100% | n/a | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 3.2× | n/a | n/a |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | 26.1× | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.48B | -26% | -23% | 5% | 9.4× | 29.5% | -3.8% |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | 53.6× | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 5.0× | 3.5% | +41.4% |
| Xiamen Amoytop Biotech 688278.SS | China | $2.56B | -27% | +18% | 27% | 4.3× | -0.6% | +36.0% |
| Xencor XNCR | United States | $2.58B | +204% | +34% | -73% | 11.7× | n/a | n/a |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| MBX Biosciences MBX | United States | $2.65B | +70% | n/a | n/a | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
Arcus Biosciences reported $256M of remaining performance obligations at 31 Dec 2025, down 51% from a year earlier and flat from the previous quarter. That is 1.0 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.